期刊文献+

上皮性卵巢肿瘤组织中端粒酶活性的表达及与临床病理因素相关性研究 被引量:1

Expression of telomerase activity and its relationship with clinical-pathological factors in epithelial ovarian tumors
下载PDF
导出
摘要 目的:探讨端粒酶在卵巢癌发 生和发展中的作用,及端粒酶活性与临 床病理因素的相关性。方法:应用端粒 重复序列扩增技术(TRAP)检测45例卵 巢上皮性肿瘤及9例正常卵巢组织端粒 酶活性。结果:端粒酶阳性检出率在恶 性和交界性卵巢肿瘤组中分别为 83.33%(25/30)和5/7,差异无统计学意 义,P=0.5963;良性上皮性卵巢肿瘤及 正常卵巢上皮组织中未检测到端粒酶活 性,与前两组之间均差异有统计学意义 P<0.01。端粒酶的表达与临床病理因 素无明显相关性。结论:端粒酶在卵巢 癌发生和发展过程中可能具有重要作 用,并有望作为卵巢上皮性癌基因治疗 的靶点。 OBJECTIVE:To investigate the role of telomerase in the development of ovarian carcinoma, and to ascertain the co-relationship between telomerase activity and clinical-pathological factors.METHODS:The telomerase repeat amplification protocol (TRAP) assay was used to examine telomerase activity in forty-five ovarian tumors and nine normal ovarian tissues.RESULTS: The positive rates of ovarian carcinoma and borderline ovarian tumors were 83.33%( 25/30) and 5/7 respectively, but none of the benign ovarian tumors and normal ovarian tissues was detected to have telomerase activity, P=0.596 3. The positive rates of telomerase activity in ovarian carcinoma and borderline ovarian tumors were significantly higher than those in benign and normal tissues,P<0.01. No relationship was found between the expression of telomerase activity and the clinical factors.CONCLUSION:Telomerase activation may contribute to the progression of ovarian carcinoma, and can probably become a promising target for gene therapy in ovarian carcinoma.
出处 《肿瘤防治杂志》 2005年第1期25-28,共4页 China Journal of Cancer Prevention and Treatment
基金 国家教委留学回国基金资助项目[教外国留(1999)363号]
关键词 上皮性卵巢肿瘤 端粒酶 端粒重复序列扩增技术 epithelial ovarian tumor telomerase telomerase repeat amplification protocol (TRAP)
  • 相关文献

参考文献9

  • 1Kim N W, Piatyszek M A, Prowse K R, et al. Specific association of human telomerase activity with immortal cells and cancer[J]. Science, 1994,266(5193): 2011-2015.
  • 2Yu J, Dubeau L. Telomerase and malignant transformation[J].Cancer Treat Res, 2002,107: 213- 228.
  • 3Novakovic S, Fras P A, Jezersek Novakovic B. Telomerase activity as a biological marker in some gynecological tumors: comparison with tissue and serum CA 125[J]. In Vivo,2001,15(4):327-332.
  • 4Sakamoto M, Toyoizumi T, Kikuchi Y, et al. Telomerase activity in gynecological tumors[J]. Oncol Rep, 2000, 7 (5): 1003-1009.
  • 5Sapi E, Okpokwasili N I, Rutherford T. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients[J]. Cancer Detect Prev,2002,26(2):158-167.
  • 6Park T W, Riethdorf S, Riethdorf L, et al. Differential telomerase Catalytic Subunit and telomerase-RNA in ovarian tumors[J]. IntJ Cancer, 1999, 84(4) :426-431.
  • 7Wan M, Li W Z, Duggan B D, et al. Telemerase activity in benign and malignant epithelial ovarian tumors [J]. J Natl Cancer Inst, 1997, 89(6): 437-441.
  • 8Kunifuji Y, Gotoh S, Abe T, et al. Down-regulation of telomerase activity by anticancer drugs in human ovarian cancer cells[J]. Anticancer Drugs,2002,13(6): 595- 598.
  • 9Wang S J, Sakamoto T, Yasuda S I S, et al. The relationship between telomere length and telomerase activity in gynecologic cancers[J]. GynecolOncol, 2002, 84(1):81-84.

同被引文献12

  • 1侯振江.环氧化酶在肿瘤监测中的应用[J].检验医学与临床,2004,1(2):76-78. 被引量:2
  • 2Murakami J, Nagai N, Ohama K, et al. Telomerase activity in ovarian tumor[ J]. Cancer, 1997,80 : 1085.
  • 3Kyo S, Kanaya T, Ishikawa H. Telomerase activity in gynecological tumors[J]. Clin Cancer Res, 1996,2:2023.
  • 4Kyo S, Takakura M, Tanaka M, et al. Quantitative differences in telomerase activity among malignant, premalignant, and benign ovarian lesions[J]. Clin Cancer Res,1998,4(2) :399-405.
  • 5Kyo S, Kanays T, Takakura M, et al. Expression of telomerase subuits in ovarian malignant, borderline and benign tumors [ J ]. Int J Cancer, 1999,80(6) :804-809.
  • 6Di-Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion [ J ]. Cancer,2002,94 (5) : 1466-1475.
  • 7Davidson B, Goldberg I, Berner A, et al. EMMPRIN ( extracellular matrix metalloproteinase inducer ) is a novel marker of poor outcome in serous ovarian carcinima [ J ]. Clin Eep Metastasis, 2003,20 ( 2 ) : 161-169.
  • 8Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase - 2 is an independent prognostic factor in human ovarian carcinoma [ J]. Am J Pathol,2002,160(3 ) :893-901.
  • 9Green JA, Robertson LJ, Clzrk AH, et al. Glutathione S-transferase expression in benign and malignant ovarian tumors [ J ]. Br J Cancer, 1993,68:235-239.
  • 10王宏,李春海,陈高明,孙丽亚,卞丽红,杨毅,毛慧生.GST-π类同工酶基因在卵巢癌组织中的表达及其与癌变的关系[J].中国肿瘤临床,1999,26(11):836-838. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部